Real-world data suggest effectiveness of the allogeneic . . . Results: The safety profile of MSC-FFM was consistent with previous reports for MSC therapies in general and MSC-FFM specifically The overall response rate at Day 28 was 46% (95% confidence interval [CI] 36-55%) in adults and 64% (45-80%) in children; most responses were durable
Effective treatment of steroid and therapy-refractory acute . . . Herein, we report the outcomes of the first 69 patients with steroid-resistant or treatment-refractory aGvHD treated with MSC-FFM in a routine clinical setting in allogeneic transplant centers across six countries
Real-world data suggest effectiveness of the allogeneic . . . The safety profile of MSC-FFM was consistent with previous reports for MSC therapies in general and MSC-FFM specifically The overall response rate at Day 28 was 46% (95% confidence interval [CI] 36–55%) in adults and 64% (45–80%) in children; most responses were durable
Real-World Data Suggest Effectiveness of Allogeneic . . . Safety: Tolerability of MSC-FFM was good, with only five adverse drug reactions reported in three adult patients (chills, BK virus cystitis, increase in C-reactive protein [reported twice in one patient], nausea) and did not result in cessation of MSC treatment or dose reductions
Real-world data suggest effectiveness of the allogeneic . . . The safety profile of MSC-FFM was consistent with previous reports for MSC therapies in general and MSC-FFM specifically The overall response rate at Day 28 was 46% (95% confidence interval [CI] 36–55%) in adults and 64% (45–80%) in children; most responses were durable